1. Scrip
  3. >>Anticancer

AstraZeneca’s Tagrisso Chemo Combo Impresses But Not A Gamechanger

Reduces Risk Of Lung Cancer Progression By 38%

 
• By Kevin Grogan

The detailed results from FLAURA2 have provided a boost for AstraZeneca's Tagrisso franchise, although the combination of the drug plus chemotherapy is unlikely to challenge the convenience that the company's biggest earner already offers for most patients.

AstraZeneca
• Source: Shutterstock: Elzbieta Krzysztof

Detailed data from the FLAURA2 Phase III trial evaluating a combination of AstraZeneca PLC's lung cancer blockbuster Tagrisso and chemotherapy have exceeded the expectations of clinicians and analysts alike but the jury is out as to whether the results will shape a radical change in care.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas